14th week of 2011 patent applcation highlights part 28 |
Patent application number | Title | Published |
20110082093 | Methods and compositions for treating trinucleotide repeat disorders - Disclosed herein are methods and compositions for treating trinucleotide repeat disorders. | 2011-04-07 |
20110082094 | Mammalian Cytokine-Like Polypeptide-10 - A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets. | 2011-04-07 |
20110082095 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 158P3D2 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization. | 2011-04-07 |
20110082096 | GENE AND PATHWAY AND THEIR USE IN METHODS AND COMPOSITIONS FOR PREDICTING ONSET OR PROGRESSION OF AUTOIMMUNE AND/OR AUTOINFLAMMATORY DISEASES - Embodiments of the present invention concern methods, compositions and uses thereof, relating to at least one of vitiligo, or vitiligo-associated autoimmune/autoinflammatory disease (VAAAD). In particular embodiments, genetic variations in the NALP1 gene are of use to detect, diagnose, predict the risk of or treat at least one of vitiligo or VAAAD. In more particular embodiments, the presence of genetic variations such as single-nucleotide polymorphisms (SNPs) in NALP1 genetic region are of use to detect, diagnose or predict the risk of VAAAD. In other embodiments, inhibitors targeted to NALP1, caspase-1 or caspase-5, ASC (PYCARD), interleukin-1β, interleukin-1β receptor, or interleukin 18 may be administered to a subject to treat VAAAD. | 2011-04-07 |
20110082097 | AMINO ACID COMPOSITION FOR IMPROVING GLUCOSE TOLERANCE - Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes. | 2011-04-07 |
20110082098 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE - Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof. | 2011-04-07 |
20110082099 | Methods and Compositions for the Treatment of Cystic Fibrosis and Related Illnesses - The present invention relates to methods and compositions to treat subjects having cystic fibrosis. These compositions comprise the class of isothiocyanates. Isothiocyanates, absorbed by a cell are conjugated with glutathione GSH by glutathione-s-tranferase (GST). The conjugates are substrates of the multi-drug resistance associated (MRP)/multi-drug resistance (MDR) proteins. These proteins are functionally redundant to the cystic fibrosis transmembrane conductance regulator (CFTR), allowing for the substrate conjugates to be exported from the cell. The export of GSH conjugates restores intracellular and extracellular levels of GSH to normal levels. Normalizing both extracellular and intracellular GSH via the increased conjugation of isothiocyanates with GSH, and subsequent export, can significantly rectify numerous enzymatic processes and correct the pathologies that are typical of patients suffering from cystic fibrosis. | 2011-04-07 |
20110082100 | THERAPEUTIC SUBSTANCES THAT MODULATE GENOME METHYLATION - Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expression and altered pattern of epigenomic control. These compounds, when used as nutrients or in other medicinal application methods, can alter the DNA methylation pattern in a simple way through the well-understood mechanism of kinetic isotope effect (KIE). This effect could also be useful for modifying methylation kinetics in stem cell technology, cloning and as disease therapeutics. | 2011-04-07 |
20110082101 | COMBINATIONS COMPRISING EPOTHILONES AND ANTI-METABOLITES - Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula I | 2011-04-07 |
20110082102 | USE OF PREBIOTIC GALACTO-OLIGOSACCHARIDES IN THE TREATMENT OF INTESTINAL INFLAMMATION - The present invention relates to the use of an oligosaccharide, in particular a non-digestible oligosaccharide, composition in the prevention or treatment of inflammation, in particular intestinal inflammation. | 2011-04-07 |
20110082103 | Anoectochilus SPP. polysaccharide extracts for stimulating growth of advantageous bacteria, stimuating release of granulocyte colony-Stimulating factor, modulating T helper cell type I, and/or modulating T helper cell type II and uses of the same | 2011-04-07 |
20110082104 | ALKYLATED SEMI SYNTHETIC GLYCOSAMINOGLYCOSAN ETHERS, AND METHODS FOR MAKING AND USING THEREOF - Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases and skin disorders. | 2011-04-07 |
20110082105 | COMPOSITIONS COMPRISING SUPERHYDROPHILIC AMPHIPHILIC COPOLYMERS AND METHODS OF USE THEREOF - Provided are compositions comprising a superhydrophilic amphiphilic copolymer and a carrier and composition comprising a superhydrophilic amphiphilic copolymer, a micellar thickener and a carrier. | 2011-04-07 |
20110082106 | METHODS OF ACTIVATING NKT CELLS - Provided are methods of activating an NKT cell which include a step of contacting the NKT cell with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell, stimulate proliferation of the NKT cell or upregulate expression of a cell surface marker on the NKT cell. Methods of activating an NKT cell population in a subject are also provided. | 2011-04-07 |
20110082107 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 - The present invention relates to compounds with the formula (I), (II), (III) or (IV): | 2011-04-07 |
20110082108 | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes - The present invention relates to inhibitors of post-proline cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of side chains in the P1 and/or P2 position of the inhibitor. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 2011-04-07 |
20110082109 | NOVEL ACYL GUANIDINE DERIVATIVES - The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na | 2011-04-07 |
20110082110 | WATER-SOLUBLE BENZOAZEPINE COMPOUND AND ITS PHARMACEUTICAL COMPOSITION - The present invention provides a benzoazepine compound represented by following general formula (1): | 2011-04-07 |
20110082111 | POLO-LIKE KINASE INHIBITORS - Compounds of the following formula are provided for use with kinases: | 2011-04-07 |
20110082112 | ANTIVIRAL PHOSPHINATE COMPOUNDS - The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound. | 2011-04-07 |
20110082113 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes prodrugs of the compound of formula (I): | 2011-04-07 |
20110082114 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors - The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-10. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophilin inhibitors. | 2011-04-07 |
20110082115 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen - The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration. | 2011-04-07 |
20110082116 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to isothiazolylidene containing compounds of Formula (I) | 2011-04-07 |
20110082117 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS - The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2011-04-07 |
20110082118 | Onychomycosis Treatment Delivery System - A topical treatment for onychomycosis and Tinea pedis comprising a delivery system further comprising at least one hydroxy acid agent having a pH-pKa value of 0.5 or greater and at least one antifungal agent formulated into creams, lotions, gels, sprays, foams, pads, films, patches, and solutions. | 2011-04-07 |
20110082119 | PROPHYLACTIC/AMELIORATING OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS - A highly safe and effective prophylactic/ameliorating or therapeutic agent for NACH and the method for using the same are provided. | 2011-04-07 |
20110082120 | SUBSTITUTED THIOACETIC ACID SALICYLATE DERIVATIVES AND THEIR USES - The invention relates to substituted thioacetic acid salicylate derivatives; compositions comprising an effective amount of a substituted thioacetic acid salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a substituted thioacetic acid salicylate derivative. | 2011-04-07 |
20110082121 | 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D | 2011-04-07 |
20110082122 | 19-Nor-Vitamin D Analogs With 1,2- or 3,2-Cyclopentene Ring - 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some types of cancers, particularly leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. | 2011-04-07 |
20110082123 | 6-Methylvitamin D3 Analogs and Their Uses - This invention discloses 6-methylvitamin D | 2011-04-07 |
20110082124 | DETERGENT COMPOSITIONS FOR TREATMENT OF LIPOMAS AND OTHER CONDITIONS - A method of treating a lipoma involves contacting the lipoma with a detergent to dissolve the lipoma. For example, the detergent may be a cholate, deoxycholate or similar detergent. A method of treating cellulite and extra fat deposits involves contacting them with a detergent to help the dissolving of the fat tissues. A method of improving the art of lipoma and extra fat removal involves using certain detergents and controlling the pH, ionic forces and/or other factors to improve detergent action. | 2011-04-07 |
20110082125 | Topical Ophthalmic or Otic Solution Formulations Containing Moxifloxacin Hydrocholoride and Dexamethasone Phosphate - Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed. | 2011-04-07 |
20110082126 | METHOD FOR TREATING INFLAMMATORY CONDITIONS - A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof. | 2011-04-07 |
20110082127 | NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE - The present invention relates to injectable progesterone formulations and processes for their preparation. | 2011-04-07 |
20110082128 | In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts - An in-situ gel ophthalmic drug delivery system for estrogen containing an estrogen, a solubilizing and complexing agent, a humectant, a sorbic acid or sorbic acid based stabilizer, an optional chelating agent and gellan gum in the amount of about 0.1-0.5% w/v, optionally 0.1-0.3% w/v, of the composition. | 2011-04-07 |
20110082129 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof. | 2011-04-07 |
20110082130 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES - Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: | 2011-04-07 |
20110082131 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS - Methods of using triazole derivatives in treating diseases or conditions associated with Axl catalytic activity are disclosed. | 2011-04-07 |
20110082132 | [4-(1-AMINO-EHTYL) - CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-EHTYL) -TETRAHYDRO-PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS - The invention relates to antibacterial compounds of formula I | 2011-04-07 |
20110082133 | PYRIDONE COMPOUNDS - [Problems] A useful compound which can be used as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease is provided. | 2011-04-07 |
20110082134 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia - The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. | 2011-04-07 |
20110082135 | INHIBITORS OF AKT ACTIVITY - The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer. | 2011-04-07 |
20110082136 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 2011-04-07 |
20110082137 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS - The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), | 2011-04-07 |
20110082138 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES - A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof. | 2011-04-07 |
20110082139 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES - The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A | 2011-04-07 |
20110082140 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. - Compounds of the formula (I), in which R | 2011-04-07 |
20110082141 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 - The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40. | 2011-04-07 |
20110082142 | SELECTIVE KINASE INHIBITORS - A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C | 2011-04-07 |
20110082143 | Bicyclic Heteroaryl Compounds - Bicyclic heteroaryl compounds of formula (I) shown below are disclosed. Each variable in formula (I) is defined in the specification. Also disclosed is treatment of cancer with these compounds. | 2011-04-07 |
20110082144 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES - This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) | 2011-04-07 |
20110082145 | OLOPATADINE COMPOSITIONS AND USES THEREOF - The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: | 2011-04-07 |
20110082146 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. | 2011-04-07 |
20110082147 | SUBSTITUTED IMIDAZOTRIAZINES - This invention relates to novel substituted imidazotriazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing partial-agonist activity at the GABA α2, α3 and α5 subtype receptors, and antagonist activity at the al subtype receptor. | 2011-04-07 |
20110082148 | TREATING, PREVENTING OR AMELIORATING A HYPERPROLIFERATIVE DISEASE/DISORDER - The invention provides a method for treating, preventing or ameliorating a hyperproliferative disease and/or disorder such as cancer (e.g. leukemia) in a mammal comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of compounds of Formula (I), quinolones and fluoroquinolones; or a pharmaceutically acceptable salt thereof to said mammal: | 2011-04-07 |
20110082149 | METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION - The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals. | 2011-04-07 |
20110082150 | Headache pre-emption by dihydroergotamine treatment during headache Precursor events - Disclosed are methods that address providing a subject experiencing, or who has experienced, a headache precursor event and administering dihydroergotamine, or a pharmaceutically acceptable salt or complex thereof, to the subject by oral inhalation, in an amount effective to pre-empt a subsequent headache in the subject. Also disclosed are compositions that are related to those methods. | 2011-04-07 |
20110082151 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR - The present invention relates to new sulfonylurea modulators of endothelin receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2011-04-07 |
20110082152 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 2011-04-07 |
20110082153 | GAMMA SECRETASE MODULATORS - This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I). | 2011-04-07 |
20110082154 | Sigma ligands for neuronal regeneration and functional recovery - The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery. | 2011-04-07 |
20110082155 | Novel 2-Pyridone Compounds - The invention provides compounds of formula | 2011-04-07 |
20110082156 | FATTY ACID ACIPIMOX DERIVATIVES AND THEIR USES - The invention relates to fatty acid acipimox derivatives; compositions comprising an effective amount of a fatty acid acipimox derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid acipimox derivative. | 2011-04-07 |
20110082157 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds - The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided. | 2011-04-07 |
20110082158 | SELECTIVE PROTON COUPLED FOLATE TRANSPORTER AND FOLATE RECEPTOR, AND GARFTASE AND/OR OTHER FOLATE METABOLIZING ENZYMES INHIBITOR COMPOUNDS AND METHODS OF USING THE SAME - Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula II: | 2011-04-07 |
20110082159 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYL- PROPANENITRILE - The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2011-04-07 |
20110082160 | SYNERGISTIC FUNGICIDAL MIXTURES FOR FUNGAL CONTROL IN CEREALS - A fungicidal composition containing a fungicidally effective amount of a compound of Formula I-V and at least one fungicide selected from the group consisting of epoxiconazole, prothioconazole, azoxystrobin, pyraclostrobin, penthiopyrad, isopyrazam, bixafen, boscalid, prochloraz, and chlorothalonil provides synergistic control of selected fungi. | 2011-04-07 |
20110082161 | POWDERS FOR RECONSTITUTION - This invention relates to drinkable formulations prepared from powders for reconstitution comprising etravirine (TMC125) dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection. | 2011-04-07 |
20110082162 | SYNERGISTIC FUNGICIDAL COMPOSITION CONTAINING 5-FLUOROCYTOSINE FOR FUNGAL CONTROL IN CEREALS - A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula I and (b) at least one fungicide selected from the group consisting of epoxiconazole, prothioconazole, azoxystrobin, pyraclostrobin, penthiopyrad, isopyrazam, bixafen, boscalid, chlorothalonil and isobutyric acid (3S,6S,7R,8R)-8-benzyl-3-[(3-isobutyryloxymethoxy-4-methoxypyridine-2-carbonyl)-amino]-6-methyl-4,9-dioxo-[1,5]dioxonan-7-yl ester provides synergistic control of selected fungi. | 2011-04-07 |
20110082163 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY - Provided is a uracil compound or a salt thereof, which has potent human dUTPase inhibitory activity and is useful as, for example, an antitumor drug. | 2011-04-07 |
20110082164 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 2011-04-07 |
20110082165 | PYRROLIDINE GPR40 MODULATORS - The present invention provides compounds of Formula (I): | 2011-04-07 |
20110082166 | NOVEL 4-BENZHYDRYL-TETRAHYDRO-PYRIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 4-benzhydryl-tetrahydro-pyridine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R | 2011-04-07 |
20110082168 | COMPOSITIONS FOR DELIVERING HIGHLY WATER SOLUBLE DRUGS - The present invention provides compositions for delivering highly water-soluble drugs (such as | 2011-04-07 |
20110082169 | Stable SNS-595 Compositions and Methods of Preparation - Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles. | 2011-04-07 |
20110082170 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF - The present invention discloses fused thienopyridyl compounds of general formula (I) | 2011-04-07 |
20110082171 | Medicaments and Methods for Inhibition of Scarring - Provided is the use of an agonist of a GABA | 2011-04-07 |
20110082172 | PYRROLIDINONE CARBOXAMIDE DERIVATIVES - Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor. | 2011-04-07 |
20110082173 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF - Compounds of formula: (I) wherein R | 2011-04-07 |
20110082174 | SOLID STATE FORMS OF RACEMIC ILAPRAZOLE - The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders. | 2011-04-07 |
20110082175 | INSECTICIDAL ARYL PYRROLIDINES - The present invention provides novel aryl pyrrolidines having an excellent insecticidal action as insecticides. Aryl pyrrolidines represented by the formula (I) and use thereof as insecticide. | 2011-04-07 |
20110082176 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases - The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis. | 2011-04-07 |
20110082177 | N'-NITROXYALKYLNICOTINAMIDES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - The invention relates to the novel N′-nitroxyalkylnicotinamide derivatives represented by the general formula I wherein R | 2011-04-07 |
20110082178 | METHODS OF TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES AND DISORDERS - Heterocyclic compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I: | 2011-04-07 |
20110082179 | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water - The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid. | 2011-04-07 |
20110082180 | ANTIMICROBIAL COMPOUNDS - The compounds disclosed herein are isoxazole derivatives that are useful as antimicrobial compounds, particularly as anti-bacterial compounds. The disclosed methods comprise incubating at least two different substrates in the presence of at least one oxygenase to provide the disclosed compounds, or to prepare and identify compounds that have antimicrobial activity. | 2011-04-07 |
20110082181 | Compounds as Lysophosphatidic Acid Receptor Antagonists - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 2011-04-07 |
20110082182 | THERAPEUTIC ANTIVIRAL PEPTIDES - Disclosed herein are compounds represented by a formula: | 2011-04-07 |
20110082183 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES - The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): (I) including tautomeric forms thereof, wherein n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones. | 2011-04-07 |
20110082184 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS - A compound comprising | 2011-04-07 |
20110082185 | CANCER-TESTIS GENE SILENCING AGENTS AND USES THEREOF - The invention relates to methods, formulations and kits useful for inhibiting cancer cell viability, invasion, or migration. | 2011-04-07 |
20110082186 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF - The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies. | 2011-04-07 |
20110082187 | MARKERS AND METHODS RELATING TO THE ASSESSMENT OF ALZHEIMER'S DISEASE - Use of clusterin as a biomarker of Alzheimer's disease (AD), particularly methods and compositions for detection of clusterin in a biological sample and assessment of in vivo pathology, disease severity and rate of clinical progression in a subject having or suspected of having AD. | 2011-04-07 |
20110082188 | GENE EXPRESSION PROFILING OF INFLAMMATORY BOWEL DISEASE - The present invention relates to methods for identifying and/or classifying patients with inflammatory bowel diseases (IBD), particularly patients with Crohn's disease or ulcerative colitis. Gene expression profiling shows broad and fundamental differences in the pathogenic mechanism of UC and CD. The subject method is based on the findings that certain genes are differentially expressed in intestinal tissue of IBD patients compared with related normal cells, such as normal colon cells. That change can be used to identify or classify IBD cells by the upregulation and/or downregulation of expression of particular genes, alterations in protein levels or modification, or changes at the genomic level (such as mutation, methylation, etc), e.g., an event which is implicated in the pathology of inflammatory bowel diseases. | 2011-04-07 |
20110082189 | USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE - The invention relates to modulation of SIRT3 activity levels. The invention has applications for regulating metabolism and mimicking caloric restriction or exercise in a muscle cell. | 2011-04-07 |
20110082190 | Nucleic Acids Encoding Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders. | 2011-04-07 |
20110082191 | METHOD FOR TREATING OR PREVENTING RADIATION DAMAGE BY IN VIVO GENE THERAPY - The current embodiment provides a method and gene therapy for treating or preventing radiation damage using a vector carrying a gene for extracellular superoxide dismutase (ECSOD). The gene therapy can be used to treat a patient with an effective amount of the therapy to limit damage resulting from exposure to radiation and radiation-like damage. | 2011-04-07 |
20110082192 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES - The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative. | 2011-04-07 |
20110082193 | TAXANE DERIVATIVE CONTAINING PHARMACEUTICAL COMPOSITION WITH IMPROVED THERAPEUTIC EFFICACY - The invention relates to a pharmaceutical combination comprising a mixture of (a) at least one taxane derivative and (b) at least one ω-3 poly-unsaturated acid or a derivative thereof wherein the molar ratio of (b) to (a) is not higher than 2. The invention further relates to a liquid pharmaceutical composition comprising (a) an effective amount of at least one taxane derivative, (b) an effective amount of at least one ω-3 poly-unsaturated fatty acid or a derivative thereof and (c) at least one pharmaceutically acceptable carrier and a process for the preparation of the same. The composition can be used for the therapy of cancers which are sensitive to taxane derivatives. The invention also relates to a kit comprising the individual components of the above mentioned composition placed in separate containers. | 2011-04-07 |